GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2007

Biotecnol Gained Access to PER.C6® for Antibody Production

  • Biotecnol obtained license rights to DSM Biologics’ and Crucell’s PER.C6® human cell line for preclinical and Phase I development of its antibody products, which are composed of Tribodies™ and compact antibodies.

    "We believe that by adopting the PER.C6 production platform, we will be able to develop our products in a robust, cost-efficient, and most importantly, in a timely way, due to its characteristics and ease of manipulation,” says Pedro de Noronha Pissarra, CEO of Biotecnol.

    Under the terms of the agreement, Biotecnol will make license payments and annual maintenance fees in exchange for certain rights.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?